NM
Newtyn Management, LLC
13F filer · CIK 0001569241Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$801MU.S. long equity reported on 13F
Positions346 new · 5 closed
Net flow last quarter-$197MBuys minus sells
Top 10 positions weight61.9%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202634 positions | |||||
| $116M | 14.49% | 9.70% | +45.3% | Q2 2024 | |
| TBTBPHTheravance Biopharma, Inc. | $58.4M | 7.29% | 6.62% | -29.1% | Q3 2019 |
| $53.6M | 6.69% | 1.07% | -34.7% | Q3 2024 | |
| $45.6M | 5.70% | 7.31% | -3.0% | Q2 2022 | |
| $42.1M | 5.26% | 5.85% | -11.5% | Q1 2022 | |
| $40.7M | 5.08% | 8.50% | -3.0% | Q1 2026 | |
| $38.7M | 4.83% | 0.69% | -23.8% | Q1 2026 | |
| $36.2M | 4.52% | 8.51% | Not reported | Q4 2020 | |
| $32.9M | 4.11% | 7.82% | +1.5% | Q4 2024 | |
| $31.3M | 3.91% | Not reported | New | Q2 2026 | |
| XRXOMAXOMA Royalty Corp | $30.1M | 3.76% | 5.66% | New | Q2 2026 |
| $29.3M | 3.65% | 2.59% | -16.5% | Q2 2025 | |
| $27.5M | 3.43% | 2.09% | -7.6% | Q2 2024 | |
| $23.4M | 2.92% | 2.61% | New | Q2 2026 | |
| $23M | 2.87% | 3.23% | +3.5% | Q1 2024 | |
| ADADArray Digital Infrastructure, Inc. | $21.7M | 2.70% | 0.69% | -63.1% | Q3 2025 |
| $19.7M | 2.46% | 1.51% | -17.9% | Q2 2025 | |
| $16.3M | 2.03% | 2.11% | +743.7% | Q1 2026 | |
| $15.9M | 1.98% | 0.80% | Not reported | Q3 2018 | |
| $15.2M | 1.90% | 3.07% | New | Q2 2026 | |
| $13.7M | 1.71% | 3.65% | +26.4% | Q2 2025 | |
| $12.2M | 1.52% | Not reported | Not reported | Q3 2022 | |
| NNODKNI Holdings, Inc. | $10.5M | 1.31% | 3.28% | Not reported | Q1 2017 |
| $10.2M | 1.28% | 0.34% | Not reported | Q2 2024 | |
| $8.21M | 1.03% | 1.33% | -93.2% | Q2 2025 | |
| AATAIAtaiBeckley Inc. | $6.26M | 0.78% | 0.32% | -33.3% | Q1 2026 |
| $5.96M | 0.74% | Not reported | +5411.3% | Q1 2026 | |
| $3.7M | 0.46% | 2.81% | +705.8% | Q1 2026 | |
| $3.68M | 0.46% | 6.87% | Not reported | Q2 2024 | |
| $3.46M | 0.43% | Not reported | New | Q2 2026 | |
| $2.98M | 0.37% | 6.64% | -19.8% | Q4 2025 | |
| $1.25M | 0.16% | 0.11% | -28.3% | Q2 2022 | |
| $953K | 0.12% | 0.38% | -57.6% | Q4 2025 | |
| $287K | 0.04% | 0.98% | New | Q2 2026 | |
| Q1 2026Reported May 15, 202633 positions | |||||
| $108M | 11.54% | Not reported | +19.6% | Q2 2025 | |
| TBTBPHTheravance Biopharma, Inc. | $78.6M | 8.40% | 9.40% | +12.6% | Q3 2019 |
| $74.9M | 8.00% | 6.69% | +51.2% | Q2 2024 | |
| ADADArray Digital Infrastructure, Inc. | $74.6M | 7.97% | 1.87% | -4.9% | Q3 2025 |
| $68.5M | 7.32% | 1.69% | +69.6% | Q3 2025 | |
| $61M | 6.51% | 1.60% | -21.1% | Q3 2024 | |
| $49.7M | 5.31% | 8.64% | +32.7% | Q4 2020 | |
| $47.8M | 5.11% | 0.91% | New | Q1 2026 | |
| $39.3M | 4.20% | 2.94% | Not reported | Q2 2025 | |
| $37.1M | 3.97% | 7.16% | -7.9% | Q2 2022 | |
| $36.4M | 3.89% | 6.63% | +543.1% | Q1 2022 | |
| $35.4M | 3.78% | 1.07% | Not reported | Q4 2024 | |
| $32.3M | 3.46% | 8.82% | New | Q1 2026 | |
| $30.1M | 3.22% | 3.20% | +14.3% | Q1 2024 | |
| $26.2M | 2.80% | 7.69% | +17.0% | Q4 2024 | |
| $24.8M | 2.65% | 2.25% | Not reported | Q2 2024 | |
| $18M | 1.92% | 1.84% | -6.4% | Q2 2025 | |
| $13.6M | 1.46% | 0.80% | -26.0% | Q3 2018 | |
| $11.3M | 1.21% | 2.90% | +19.5% | Q2 2025 | |
| $10.6M | 1.14% | Not reported | Not reported | Q3 2022 | |
| $9.24M | 0.99% | Not reported | New | Q1 2026 | |
| NNODKNI Holdings, Inc. | $8.64M | 0.92% | 3.27% | Not reported | Q1 2017 |
| $8.38M | 0.90% | 0.41% | +35.2% | Q4 2025 | |
| $7.75M | 0.83% | 0.36% | Not reported | Q2 2024 | |
| AATAIAtaiBeckley Inc. | $6.31M | 0.67% | 0.49% | New | Q1 2026 |
| $4.75M | 0.51% | 6.90% | Not reported | Q2 2024 | |
| $4.03M | 0.43% | 8.27% | -3.5% | Q4 2025 | |
| $2.34M | 0.25% | 0.89% | +3051.5% | Q4 2025 | |
| $2.18M | 0.23% | 0.16% | Not reported | Q2 2022 | |
| $1.6M | 0.17% | 0.25% | New | Q1 2026 | |
| $1.43M | 0.15% | 0.14% | Not reported | Q2 2022 | |
| $624K | 0.07% | 0.35% | New | Q1 2026 | |
| $116K | 0.01% | Not reported | New | Q1 2026 | |
| Q4 2025Reported Feb 17, 202631 positions | |||||
| ADADArray Digital Infrastructure, Inc. | $91.2M | 9.58% | 1.97% | +25.9% | Q3 2025 |
| $90.9M | 9.55% | 2.03% | -39.7% | Q3 2024 | |
| $86.1M | 9.05% | 4.44% | +11.7% | Q2 2024 | |
| $82.4M | 8.66% | Not reported | +171.7% | Q2 2025 | |
| TBTBPHTheravance Biopharma, Inc. | $80.5M | 8.45% | 8.42% | -13.1% | Q3 2019 |
| $55.8M | 5.86% | 7.60% | +4.0% | Q2 2022 | |
| $54.6M | 5.74% | 6.56% | +18.5% | Q4 2020 | |
| $50M | 5.26% | 2.85% | -3.0% | Q2 2025 | |
| $43.1M | 4.53% | 1.60% | New | Q4 2025 | |
| $40.2M | 4.23% | 0.99% | +269.8% | Q3 2025 | |
| $35.7M | 3.75% | 6.63% | +4.4% | Q4 2024 | |
| $30.2M | 3.17% | 2.80% | +100.0% | Q1 2024 | |
| $26.6M | 2.80% | 2.22% | -8.7% | Q2 2024 | |
| $20.5M | 2.16% | Not reported | -52.3% | Q2 2022 | |
| COCIOCity Office REIT, Inc. | $19.6M | 2.06% | 6.94% | -28.9% | Q3 2021 |
| $16.2M | 1.70% | 1.97% | -4.7% | Q2 2025 | |
| $15.4M | 1.62% | 1.05% | Not reported | Q1 2022 | |
| $14.8M | 1.55% | 1.07% | Not reported | Q3 2018 | |
| $13.8M | 1.45% | Not reported | +39.1% | Q3 2022 | |
| $12.8M | 1.35% | 0.37% | -25.0% | Q2 2024 | |
| $9.3M | 0.98% | 2.45% | +5.9% | Q2 2025 | |
| $8.96M | 0.94% | Not reported | Not reported | Q1 2025 | |
| NNODKNI Holdings, Inc. | $8.91M | 0.94% | 3.26% | Not reported | Q1 2017 |
| $6.96M | 0.73% | 0.19% | New | Q4 2025 | |
| $6.81M | 0.72% | 0.31% | New | Q4 2025 | |
| $6.76M | 0.71% | 6.90% | Not reported | Q2 2024 | |
| $6.08M | 0.64% | 8.57% | New | Q4 2025 | |
| $5.1M | 0.54% | 0.16% | Not reported | Q2 2022 | |
| $3.32M | 0.35% | Not reported | New | Q4 2025 | |
| $2.49M | 0.26% | 0.74% | New | Q4 2025 | |
| $93.6K | 0.01% | 0.03% | New | Q4 2025 | |
| Q3 2025Reported Nov 14, 202533 positions | |||||
| $101M | 12.40% | 3.37% | +61.1% | Q3 2024 | |
| $79.5M | 9.73% | 3.98% | +58.3% | Q2 2024 | |
| TBTBPHTheravance Biopharma, Inc. | $72.3M | 8.85% | 9.77% | Not reported | Q3 2019 |
| ADADArray Digital Infrastructure, Inc. | $67.5M | 8.26% | 1.56% | New | Q3 2025 |
| $62.5M | 7.65% | 6.61% | -22.9% | Q2 2022 | |
| $61.6M | 7.53% | 5.54% | +49.5% | Q4 2020 | |
| $37.5M | 4.59% | Not reported | +10.0% | Q2 2022 | |
| $30.8M | 3.77% | 2.43% | -7.5% | Q2 2024 | |
| COCIOCity Office REIT, Inc. | $27.4M | 3.36% | 9.76% | Not reported | Q3 2021 |
| $26.8M | 3.29% | 1.43% | +12.0% | Q1 2024 | |
| $26.5M | 3.24% | 6.35% | -0.5% | Q4 2024 | |
| $21.5M | 2.63% | Not reported | +69.1% | Q2 2025 | |
| $18M | 2.21% | 2.93% | -9.1% | Q2 2025 | |
| $17.4M | 2.14% | 3.69% | +76.1% | Q2 2025 | |
| $16.8M | 2.06% | 1.05% | 0.0% | Q1 2022 | |
| $16.6M | 2.03% | 2.07% | -32.4% | Q2 2025 | |
| $13.6M | 1.67% | Not reported | New | Q3 2025 | |
| $13.1M | 1.61% | 1.03% | Not reported | Q3 2018 | |
| $11.8M | 1.45% | 0.55% | Not reported | Q2 2024 | |
| 8ETNB89bio, Inc. | $11.8M | 1.44% | 0.54% | +300.0% | Q2 2022 |
| $11.6M | 1.42% | Not reported | +56.4% | Q3 2022 | |
| $11.4M | 1.40% | 6.90% | Not reported | Q2 2024 | |
| $9.7M | 1.19% | 0.04% | -19.1% | Q1 2024 | |
| $9.29M | 1.14% | 0.27% | New | Q3 2025 | |
| $9.26M | 1.13% | 0.19% | New | Q3 2025 | |
| NNODKNI Holdings, Inc. | $9.09M | 1.11% | 3.25% | Not reported | Q1 2017 |
| $8.16M | 1.00% | 2.31% | +25.1% | Q2 2025 | |
| SSCPHScpharmaceuticals Inc. | $5.33M | 0.65% | 1.76% | New | Q3 2025 |
| $2.76M | 0.34% | 0.29% | New | Q3 2025 | |
| $2.2M | 0.27% | 0.19% | -25.0% | Q2 2022 | |
| $1.43M | 0.17% | 0.63% | -15.1% | Q2 2023 | |
| $1.31M | 0.16% | 0.47% | -48.2% | Q2 2024 | |
| MOMURAMural Oncology plc | $1.08M | 0.13% | 3.02% | -8.3% | Q4 2023 |
Premium opens every quarter this fund has filed